Reverses Factor Xa inhibitors (apixaban, rivaroxaban) by acting as a decoy substrate. Dosing is weight- and time-since-last-dose dependent. Notable for a rebound anticoagulant effect after the infusion stops, and for an associated thrombotic risk, which must be weighed against the bleeding emergency being treated.
Related terms
Study RCIS & RCES terms in context
Cardiac Codex turns definitions like this into a full study system: 177 lessons, 2,233 practice questions with explanations, blueprint-matched mock exams, and Cardiac Coach — an AI tutor grounded in this exact glossary you can ask from any lesson.
Get early access Back to the glossary →
Cardiac Codex is an independent study tool published by MdoubleA LLC, not affiliated with or endorsed by CCI or any certifying body. This glossary entry is exam-preparation information, not medical advice or a substitute for clinical judgment. Always verify current clinical practice against primary sources and institutional protocol.